ArticleGenetics2015
In Vivo Transcriptional Activation Using CRISPR/Cas9 in Drosophila.
Article in Genetics, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 76 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
76 citing papers in PubMed, 149 citations in OpenAlex.
- Embedded CRISPRi Enhances Gene-Silencing Efficiency in Drosophila.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2026Article
- Article
- Epigenetic editing of marine medaka (Zoological research · 2026Article
- Recruitment of transcriptional effectors by Cas9 createsiScience · 2026Article
- The use ofFrontiers in cell and developmental biology · 2026Review
- Heat shock-optimized CRISPR/Cas9 system for visible clonal analysis and mutant generation in Drosophila.G3 (Bethesda, Md.) · 2025Article
- Epigenetics and individuality: from concepts to causality across timescales.Nature reviews. Genetics · 2025Review
- A polycistronic locus encodes both a tumor-suppressive microRNA and a long non-coding RNA regulating testis morphology in Drosophila.bioRxiv : the preprint server for biology · 2025Article
- Expression Pattern of the AB1-Gal4 Driver inInternational journal of molecular sciences · 2025Article
- A systematic screening assay identifies efficient small guide RNAs for CRISPR activation.Frontiers in bioengineering and biotechnology · 2025Article
- A novelFly · 2024Article
- Retinoblastoma protein activity revealed by CRISPRi study of divergent Rbf1 and Rbf2 paralogs.G3 (Bethesda, Md.) · 2024Article
- The MondoA-dependent TXNIP/GDF15 axis predicts oxaliplatin response in colorectal adenocarcinomas.EMBO molecular medicine · 2024Article
- Systems for Targeted Silencing of Gene Expression and Their Application in Plants and Animals.International journal of molecular sciences · 2024Review
- Serine hydroxymethyl transferase is required for optic lobe neuroepithelia development in Drosophila.Development (Cambridge, England) · 2023Article
- CRISPR/dCas9 Tools: Epigenetic Mechanism and Application in Gene Transcriptional Regulation.International journal of molecular sciences · 2023Review
- tgCRISPRi: efficient gene knock-down using truncated gRNAs and catalytically active Cas9.Nature communications · 2023Article
- Technological advances in mosquito olfaction neurogenetics.Trends in genetics : TIG · 2023Review
- CRISPR mediated transactivation in the human disease vector Aedes aegypti.PLoS pathogens · 2023Article
- Different transcriptional responses by the CRISPRa system in distinct types of heterochromatin in Drosophila melanogaster.Scientific reports · 2022Article
16 more citing papers are in PubMed but not listed here.
Corrections and comments
- Erratum issuedCorrigendum.2015
Authors and funding
5 authors at 2 institutions in 2 countries.
Funding
Abstract
A number of approaches for Cas9-mediated transcriptional activation have recently been developed, allowing target genes to be overexpressed from their endogenous genomic loci. However, these approaches have thus far been limited to cell culture, and this technique has not been demonstrated in vivo in any animal. The technique involving the fewest separate components, and therefore the most amenable to in vivo applications, is the dCas9-VPR system, where a nuclease-dead Cas9 is fused to a highly active chimeric activator domain. In this study, we characterize the dCas9-VPR system in Drosophila cells and in vivo. We show that this system can be used in cell culture to upregulate a range of target genes, singly and in multiplex, and that a single guide RNA upstream of the transcription start site can activate high levels of target transcription. We observe marked heterogeneity in guide RNA efficacy for any given gene, and we confirm that transcription is inhibited by guide RNAs binding downstream of the transcription start site. To demonstrate one application of this technique in cells, we used dCas9-VPR to identify target genes for Twist and Snail, two highly conserved transcription factors that cooperate during Drosophila mesoderm development. In addition, we simultaneously activated both Twist and Snail to identify synergistic responses to this physiologically relevant combination. Finally, we show that dCas9-VPR can activate target genes and cause dominant phenotypes in vivo, providing the first demonstration of dCas9 activation in a multicellular animal. Transcriptional activation using dCas9-VPR thus offers a simple and broadly applicable technique for a variety of overexpression studies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.